– USA, FL – Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for chronic, aging-related, and life-threatening conditions, today announced the appointment of Todd Girolamo to its Board of Directors.
“Mr. Girolamo will bring invaluable legal, finance and biopharmaceutical development insight and leadership to our Board. The extensive depth and breadth of Todd’s experience in biopharma, particularly cell and gene therapy, will provide a valuable resource as we advance Lomecel-B through downstream phases of clinical development and towards prospective commercial launch,” said CEO, Geoff Green.
About Todd Girolamo
Todd Girolamo is a seasoned attorney and biopharmaceutical executive specializing in health-related products, currently serving as Chief Legal Officer, SVP of Corporate Development, and Corporate Secretary for Caladrius Biosciences, Inc. (NASDAQ: CLBS).
Girolamo’s experience includes Securities and Exchange Commission, stock exchange, Food and Drug Administration compliance, corporate finance, M&A, and licensing activities. He has further experience with intellectual property, litigation, and drug development.
“I am excited to have the opportunity to join Longeveron’s Board and help build on the foundation in cellular therapy research and execution of clinical trials that it has achieved over the last several years,” said Todd Girolamo. “With early trials of Lomecel-B showing exciting promise in areas like aging frailty, Alzheimer’s and Hyperplastic Left Heart Syndrome, Longeveron presents an opportunity to advance potential new life-altering therapies for patients in need.”
Girolamo’s private practice legal experience includes stints at Reid & Priest and Cahill, Gordon & Reindel. In addition to his time practicing law, Girolamo spent 12 years on Wall Street, specializing in therapeutic healthcare equity securities with Oppenheimer & Co., CIBC World Markets, Leerink & Company, and Summer Street Research Partners. Before going in-house at Caladrius, Girolamo served as an analyst and portfolio manager at Lion’s Path Capital, managing a long-short portfolio of biopharma and med-tech equities.
Todd Girolamo has an AB from Harvard College, a JD from the University of Pennsylvania Law School, and an MBA from Columbia Business School.
About Longeveron Inc.
Longeveron is a clinical-stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. The Company’s lead investigational product is the LOMECEL-B cell-based therapy product, which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from the bone marrow of young, healthy adult donors. Longeveron believes that by using the same cells that promote tissue repair, organ maintenance, and immune system function, it can develop safe and effective therapies for some of the most difficult disorders associated with the aging process and other medical disorders. Longeveron is currently sponsoring Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimer’s disease, Metabolic Syndrome, Acute Respiratory Distress Syndrome, and hypoplastic left heart syndrome. The Company’s mission is to advance Lomecel-B and other cell-based product candidates into pivotal Phase 3 trials, to achieve regulatory approvals, subsequent commercialization, and broad use by the healthcare community.
For more information: https://www.longeveron.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.